Treating lung cancer in non-smokers: the next step

Study Objective

1. The improvement of the diagnostic performance in non-small cell lung cancer (NSCLC) in non-smokers.
2. A better understanding of the failure of specific treatments.
3. A better prediction of the probability that specific drugs will induce response based on the specific genomics of the tumor.
4. An early definition of the most effective treatments for the patient resulting in a better individualization of these treatments.

Participation conditions

Inclusion criteria

 Patients with NSCLC either at diagnosis or relapse after surgery
 Non-smoking or former limited smoking history of less than 5 packed years with a smoking free interval of more than 20 years
 Smoking history with EGFR positive mutation or other known druggable driver mutation
 No previous systemic treatment for advanced NSCLC. Previous adjuvant chemotherapy after surgery is permitted
 Early stage NSCLC patients treated with surgery may be included before the start of adjuvant systemic chemotherapy
 In case of relapse of NSCLC after surgery, a new biopsy for the study is mandatory before the start of any treatment
 Signed and dated informed consent by the patient
 No additional restrictions apply

Exclusion criteria

 Absence of informed consent for tumor biopsy and/or analysis of germline DNA
 Absence of available baseline tumor tissue
 Absence of available germline DNA sample
 

Centre Hospitalier de Luxembourg (CHL)